Meropenem Anfarm (Meropenem Anhydrous)

Meropenem belongs to the carbapenem class and works by binding to penicillin‑binding proteins on bacterial cell walls. This binding blocks the cross‑linking of peptidoglycan strands, weakening the wall and causing bacterial cell lysis. The result is a rapid, bactericidal effect against many Gram‑positive, Gram‑negative, and anaerobic organisms, including resistant strains.

The dosing regimen for Meropenem Anfarm is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals calculate the appropriate intravenous dose and infusion rate for each individual patient.

The safety of Meropenem Anfarm in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Meropenem Anfarm product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Meropenem offers a broader spectrum against Pseudomonas aeruginosa and many resistant Gram‑negative organisms compared with imipenem, and it has a lower risk of seizures than imipenem. Unlike ertapenem, which lacks activity against Pseudomonas and Acinetobacter, meropenem retains potency against these pathogens, making it a preferred choice for severe, high‑risk infections.

Meropenem Anfarm should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If the product is reconstituted, use it within the time frame specified in the package insert and maintain refrigeration until administration.

Meropenem Anfarm is supplied as a sterile powder for injection. After reconstitution with the appropriate diluent, it is administered intravenously, typically over a 15‑30 minute infusion. The exact infusion rate and dosing schedule are determined by the treating physician based on infection severity and patient-specific factors.

The most serious adverse events include seizures (especially in patients with renal impairment or pre‑existing CNS disorders), severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant neutropenia or leukopenia. Clinicians should monitor patients closely for neurological changes, rash, gastrointestinal symptoms, and blood count abnormalities.

Meropenem Anfarm is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal impairment without dose adjustment, or those receiving valproic acid, due to increased risk of neurotoxicity.